alk gene rearrangement positive
Showing 1 - 5 of 5
NSCLC, ALK Gene Rearrangement Positive Trial in United States (Ensartinib)
Available
- Non-Small Cell Lung Cancer
- ALK Gene Rearrangement Positive
-
Stanford, California
- +3 more
Oct 18, 2022
Nsclc, EGFR Activating Mutation, EGF-R Positive NSCLC Trial in Hong Kong (Pembrolizumab, Lenvatinib, Pemetrexed)
Recruiting
- Nsclc
- +5 more
- Pembrolizumab
- +3 more
-
Hong Kong, Hong KongQueen Mary Hospital
Nov 25, 2021
NSCLC, ALK Gene Rearrangement Positive Trial in France (RNAseq)
Recruiting
- Non-small Cell Lung Cancer
- ALK Gene Rearrangement Positive
- RNAseq
-
Saint-Denis, La Réunion, France
- +44 more
Nov 4, 2021
NSCLC Stage IIIB, NSCLC Stage IV, EGFR Gene Mutation Trial in France (Carboplatin + Pemetrexed + Atezolizumab + Bevacizumab,
Recruiting
- NSCLC Stage IIIB
- +4 more
- Carboplatin + Pemetrexed + Atezolizumab + Bevacizumab
- Carboplatin + Pemetrexed + Atezolizumab
-
Angers, France
- +30 more
Jun 7, 2021
ALK Gene Rearrangement Positive, Non-Squamous Non-Small Cell Tumor of Lung Trial in Mexico City (Alectinib, Bevacizumab)
Unknown status
- ALK Gene Rearrangement Positive
- Non-Squamous Non-Small Cell Neoplasm of Lung
-
Mexico City, MexicoInstituto Nacional de Cancerologia
Feb 8, 2021